Neural tube defects, folate, and immune modulation

Denny, Kerina J.; Jeanes, Angela; Fathe, Kristin; Finnell, Richard H.; Taylor, Stephen M.; Woodruff, Trent M.

doi:10.1002/bdra.23177

Cited by 46 publications

(49 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elevated concentrations of Hcy and low concentrations of folate may exert detrimental effects on cognitive function by inducing systemic inflammation3435. Furthermore, folate plays a well-known role in maintaining the immune system36. Here, reducing the Hcy concentrations via folic acid supplementation ameliorated these effects.…”

Section: Discussionmentioning

confidence: 99%

Folic acid supplementation improves cognitive function by reducing the levels of peripheral inflammatory cytokines in elderly Chinese subjects with MCI

Zhao³

et al. 2016

Sci Rep

View full text Add to dashboard Cite

This study aimed to evaluate whether folic acid supplementation would improve cognitive performance by reducing serum inflammatory cytokine concentrations. This RCT was performed in Tianjin, China. Participants with mild cognitive impairment (MCI) were randomly assigned to the folic acid (400 μg/day) or conventional treatment groups. Neuropsychological tests were administered, and folate, homocysteine, vitamin B12, IL-6, TNF-α, Aβ-42, and Aβ-40 were measured at baseline and at 6- and 12-month time points.152 participants (folic acid: 77, conventional: 75) completed the trial. Significant improvements in folate (ηp2 = 0.703, P = 0.011), homocysteine (ηp2 = 0.644, P = 0.009), Aβ-42 (ηp2 = 0.687, P = 0.013), peripheral IL-6 (ηp2 = 0.477, P = 0.025), TNF-α (ηp2 = 0.709, P = 0.009) levels were observed in folic acid group compared with conventional group. Folic acid supplementation improved the Full Scale Intelligence Quotient (P = 0.028; effect size d = 0.153), Information (P = 0.031; d = 0.157) and Digit Span (P = 0.009; d = 0.172) scores at 12 months compared with conventional treatment. Based on these findings, daily oral administration of a 400-μg folic acid supplement to MCI subjects for 12 months can significantly improve cognitive performance and reduce peripheral inflammatory cytokine levels.

show abstract

Section: Discussionmentioning

confidence: 99%

Folic acid supplementation improves cognitive function by reducing the levels of peripheral inflammatory cytokines in elderly Chinese subjects with MCI

Zhao³

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Additional scientific evidence could also refine and improve the undisputed effectiveness of folic acid supplementation. Issues for research include the characterization of effects on CA other than neural tube defects [38,39], the 5-methyl-tetrahydrofolate as possible alternative to folic acid [40] and the mechanisms (immune factors, inositol metabolism) and risk factors of the neural tube defects that are resistant to folic acid supplementation [41,42]. Most importantly, folic acid is also an issue for public health research, e.g., strategies to promote a community awareness on periconceptional supplementation [43] and a robust and consistent definition of recommended intake levels for folates [44].…”

Section: Tablementioning

confidence: 99%

Primary Prevention of Congenital Anomalies: Recommendable, Feasible and Achievable

Taruscio

Mantovani

Carbone

et al. 2015

Public Health Genomics

View full text Add to dashboard Cite

Primary prevention of congenital anomalies was identified as an important action in the field of rare diseases by the European Commission in 2008, but it was not included in the Council Recommendation on an action in the field of rare diseases in 2009. However, primary prevention of congenital anomalies is feasible because scientific evidence points to several risk factors (e.g., obesity, infectious and toxic agents) and protective factors (e.g., folic acid supplementation and glycemic control in diabetic women). Evidence-based community actions targeting fertile women can be envisaged, such as risk-benefit evaluation protocols on therapies for chronic diseases, vaccination policies, regulations on workplace and environmental exposures as well as the empowerment of women in their lifestyle choices. A primary prevention plan can identify priority targets, exploit and integrate ongoing actions and optimize the use of resources, thus reducing the health burden for the new generation. The EUROCAT-EUROPLAN recommendations for the primary prevention of congenital anomalies endorsed in 2013 by the European Union Committee of Experts on Rare Diseases present an array of feasible and evidence-based measures from which national plans can adopt and implement actions based on country priorities. Primary prevention of congenital anomalies can be achieved here and now and should be an integral part of national plans on rare diseases.

show abstract

“…Dans ces cas, il est souvent judicieux de différer de quelques semaines ou de quelques mois une grossesse, afin de vérifier que les adaptations réalisées sont bien tolérées et permettent le contrôle de la pathologie sous-jacente [7]. Une supplémentation en folates est systématique, indispensable en cas de traitement antérieur par méthotrexate ou d'anémie hémolytique même bien compensée, dans le but de limiter le risque d'anomalie de fermeture du tube neural [8]. Un apport en calcium et en vitamine D est vivement recommandé, en particulier en cas de corticothérapie et de traitement par héparine.…”

Section: Adaptation Des Traitementsunclassified